Literature DB >> 34435786

Subtle Chemical Changes Cross the Boundary between Agonist and Antagonist: New A3 Adenosine Receptor Homology Models and Structural Network Analysis Can Predict This Boundary.

Yoonji Lee1,2, Xiyan Hou3,4, Jin Hee Lee1, Akshata Nayak3, Varughese Alexander3, Pankaz K Sharma1, Hyerim Chang1, Khai Phan5, Zhan-Guo Gao5, Kenneth A Jacobson5, Sun Choi1, Lak Shin Jeong3.   

Abstract

Distinguishing compounds' agonistic or antagonistic behavior would be of great utility for the rational discovery of selective modulators. We synthesized truncated nucleoside derivatives and discovered 6c (Ki = 2.40 nM) as a potent human A3 adenosine receptor (hA3AR) agonist, and subtle chemical modification induced a shift from antagonist to agonist. We elucidated this shift by developing new hA3AR homology models that consider the pharmacological profiles of the ligands. Taken together with molecular dynamics (MD) simulation and three-dimensional (3D) structural network analysis of the receptor-ligand complex, the results indicated that the hydrogen bonding with Thr943.36 and His2727.43 could make a stable interaction between the 3'-amino group with TM3 and TM7, and the corresponding induced-fit effects may play important roles in rendering the agonistic effect. Our results provide a more precise understanding of the compounds' actions at the atomic level and a rationale for the design of new drugs with specific pharmacological profiles.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34435786      PMCID: PMC8840841          DOI: 10.1021/acs.jmedchem.1c00239

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   8.039


  43 in total

Review 1.  A(3) adenosine receptor ligands: history and perspectives.

Authors:  P G Baraldi; B Cacciari; R Romagnoli; S Merighi; K Varani; P A Borea; G Spalluto
Journal:  Med Res Rev       Date:  2000-03       Impact factor: 12.944

Review 2.  Tactical Approaches to Interconverting GPCR Agonists and Antagonists.

Authors:  Peter I Dosa; Elizabeth Ambrose Amin
Journal:  J Med Chem       Date:  2015-09-21       Impact factor: 7.446

3.  Structure-activity relationships of 2-chloro-N6-substituted-4'-thioadenosine-5'-uronamides as highly potent and selective agonists at the human A3 adenosine receptor.

Authors:  Lak Shin Jeong; Hyuk Woo Lee; Kenneth A Jacobson; Hea Ok Kim; Dae Hong Shin; Jeong A Lee; Zhan-Guo Gao; Changrui Lu; Heng T Duong; Prashantha Gunaga; Sang Kook Lee; Dong Zhe Jin; Moon Woo Chun; Hyung Ryong Moon
Journal:  J Med Chem       Date:  2006-01-12       Impact factor: 7.446

4.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

Review 5.  The A3 adenosine receptor: history and perspectives.

Authors:  Pier Andrea Borea; Katia Varani; Fabrizio Vincenzi; Pier Giovanni Baraldi; Mojgan Aghazadeh Tabrizi; Stefania Merighi; Stefania Gessi
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

6.  N6-substituted D-4'-thioadenosine-5'-methyluronamides: potent and selective agonists at the human A3 adenosine receptor.

Authors:  Lak Shin Jeong; Dong Zhe Jin; Hea Ok Kim; Dae Hong Shin; Hyung Ryong Moon; Prashantha Gunaga; Moon Woo Chun; Yong-Chul Kim; Neli Melman; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2003-08-28       Impact factor: 7.446

7.  The antitumor effect of LJ-529, a novel agonist to A3 adenosine receptor, in both estrogen receptor-positive and estrogen receptor-negative human breast cancers.

Authors:  Heekyoung Chung; Ji-Youn Jung; Sung-Dae Cho; Kyung-A Hong; Hyun-Jun Kim; Dong-Hui Shin; Hwan Kim; Hea Ok Kim; Dae Hong Shin; Hyuk Woo Lee; Lak Shin Jeong; Gu Kong
Journal:  Mol Cancer Ther       Date:  2006-03       Impact factor: 6.261

8.  Consistent improvement of cross-docking results using binding site ensembles generated with elastic network normal modes.

Authors:  Manuel Rueda; Giovanni Bottegoni; Ruben Abagyan
Journal:  J Chem Inf Model       Date:  2009-03       Impact factor: 4.956

9.  Structural determinants of efficacy at A3 adenosine receptors: modification of the ribose moiety.

Authors:  Zhan-Guo Gao; Lak Shin Jeong; Hyung Ryong Moon; Hea Ok Kim; Won Jun Choi; Dae Hong Shin; Eleonora Elhalem; Maria J Comin; Neli Melman; Liaman Mamedova; Ariel S Gross; Juan B Rodriguez; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2004-03-01       Impact factor: 5.858

10.  Structure of the adenosine A(2A) receptor bound to an engineered G protein.

Authors:  Byron Carpenter; Rony Nehmé; Tony Warne; Andrew G W Leslie; Christopher G Tate
Journal:  Nature       Date:  2016-07-27       Impact factor: 49.962

View more
  4 in total

1.  Design, Synthesis and Biological Evaluation of 1,3,5-Triazine Derivatives Targeting hA1 and hA3 Adenosine Receptor.

Authors:  Sujin Park; Yujin Ahn; Yongchan Kim; Eun Joo Roh; Yoonji Lee; Chaebin Han; Hee Min Yoo; Jinha Yu
Journal:  Molecules       Date:  2022-06-22       Impact factor: 4.927

Review 2.  Current Adenosinergic Therapies: What Do Cancer Cells Stand to Gain and Lose?

Authors:  Jana Kotulová; Marián Hajdúch; Petr Džubák
Journal:  Int J Mol Sci       Date:  2021-11-22       Impact factor: 5.923

3.  Discovery of Pyridone-Substituted Triazolopyrimidine Dual A2A/A1 AR Antagonists for the Treatment of Ischemic Stroke.

Authors:  Mei-Lin Tang; Zi-Hao Wen; Jing-Huan Wang; Mei-Ling Wang; Heyanhao Zhang; Xin-Hua Liu; Lin Jin; Jun Chang
Journal:  ACS Med Chem Lett       Date:  2022-02-21       Impact factor: 4.345

4.  GPCR Agonist-to-Antagonist Conversion: Enabling the Design of Nucleoside Functional Switches for the A2A Adenosine Receptor.

Authors:  Anna Shiriaeva; Daejin Park; Gyudong Kim; Yoonji Lee; Xiyan Hou; Dnyandev B Jarhad; Gibae Kim; Jinha Yu; Young Eum Hyun; Woomi Kim; Zhan-Guo Gao; Kenneth A Jacobson; Gye Won Han; Raymond C Stevens; Lak Shin Jeong; Sun Choi; Vadim Cherezov
Journal:  J Med Chem       Date:  2022-08-17       Impact factor: 8.039

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.